IMHO, lots of good indicators - numerous key clinical experts involved, multiple pedigree med institutes, multiple indications of support from FDA, great paxalisib early data, good cash, multiple pull (investigator led) studies, invitation to world leading registration study.
Just waiting on data now.
GLTA.
Add to My Watchlist
What is My Watchlist?